AMPICLOX DRY COW

Main information

  • Trade name:
  • AMPICLOX DRY COW INTRAMAMMARY ANTIBIOTIC INFUSION
  • Pharmaceutical form:
  • MISC. INTRA MAMMARY
  • Units in package:
  • 20x3.8gSyringe, 200x3.8gSyringe
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • AMPICLOX DRY COW INTRAMAMMARY ANTIBIOTIC INFUSION
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • COW-NOT LACTATING-PREG. NOT W/I 1MTH CAL | DAIRY CATTLE DRY | DAIRY CATTLE LACTATING | BOVINE | COW | COW PREGNANT NOT WITHIN 1
  • Therapeutic area:
  • antibiotic
  • Therapeutic indications:
  • ANTIBIOTIC - ANTI-INFECTIVE | ABRASIONS | ABSCESSES | AIRSACCULITIS | ANTISEPTIC | AVIAN MYCOPLASMAS | BLACKHEAD | BODY ODOURS | BOWED TENDONS | BROAD SPECTRUM | BURNS | COCCIDIOSIS | COLIFORM COMPLEX | CONJUNCTIVITIS | COWPOX | CRACKS | CRUSTS | DANDRUFF | DERMATOLOGICAL DISORDERS | DERMATOSIS | DRY SKIN | DYSENTERY | ECZEMA | ENDOMETRITIS | ENTERIC DISEASES | ENZOOTIC PNEUMONIA | FEED EFFICIENCY | FUNGAL INFECTIONS | GIRTH GALLS | INFECTIONS | INFLAMMED PADS | ITCHING | KERATOLYTIC | LACERATIONS | MASTITIS | MYCOPLASMAS | ODOURS | OPEN WOUNDS | OTITIS | PRURITIS | QUEENSLAND ITCH | RESPIRATORY DISEASE | SADDLE RASH | SALMONELLOSIS | SCABS | SCALY SKIN | SHEATH ROT | SKIN IRRITATIONS | SORES | SWINE DYSENTERY | TEAT CRACKING | TEAT INFECTIONS | TOPICAL INFECTIONS | UDDER SORES | WEIGHT GAIN | WIRE CUTS | WOUNDS
  • Product summary:
  • For treatment of bovine mastitis caused by organisms sensitive to ampicillin and cloxacillin, during the dry period.Not to be used in lactating cows or within 30 days of calving. If accidently administered within 30 days of calving or to a lactating animal, contact your prescribing veterinarian for advice. Do not use in cows exhibiting sensitivity to penicillin

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered and available
  • Authorization number:
  • 35842/1208
  • Authorization date:
  • 22-04-2009
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

APPROVED

LABEL

Info

pest

Verified

APPROVED

LABEL

Info

pest

Verified

168mm

Overall size 90mm x 168mm is 100% size 90mm x 168mm folded to 90mm x 23mm

90mm

90mm

APVMA file name: 35842_46325_leaflet_MPL_V01.pdf

Dimensions: leaflet = 90mm x 168mm per side

Scale: 100% on A4

Date: 11 – 3 – 2009

PRESCRIPTION ANIMAL REMEDY

KEEP OUT OF REACH OF CHILDREN

FOR ANIMAL TREATMENT ONLY

Ampiclox

DRY COW

INTRAMAMMARY ANTIBIOTIC INFUSION

For the treatment of Bovine Mastitis caused by organisms sensitive

to Ampicillin and Cloxacillin during the Dry Period.

PRODUCT SUMMARY: Ampiclox

Dry Cow Intramammary Antibiotic

Infusion is formulated for routine treatment of cows at drying off.

Ampiclox

Dry Cow Intramammary Antibiotic Infusion is broad spectrum

in activity and active against all the major causative organisms of mastitis.

Ampiclox

is active against Penicillin resistant Staphylococci, commonly

involved in mastitis.

The formulation and base provide effective concentrations in the udder to

eliminate the majority of existing infections and to reduce substantially the

incidence of new infections.

DESCRIPTION: Ampiclox

Dry Cow Intramammary Antibiotic Infusion is

a stable suspension of Ampicillin Trihydrate, equivalent to 250mg of

Ampicillin and Cloxacillin Benzathine equivalent to 500mg of

Cloxacilllin in

a long acting base.

Ampicillin and Cloxacillin are semi-synthetic penicillins derived from the

penicillin nucleus, 6-aminopenicillanic acid, first isolated by Beecham

Research Laboratories.

It is presented in syringes for intramammary infusion and is designed to

be used in the dairy cow at the point of drying off, that is, immediately after

the last milking of the lactation.

ACTION: Ampiclox

Dry Cow Intramammary Antibiotic Infusion is active

against all the major causative organisms of mastitis, both Gram-positive

and Gram-negative. It is effective against:

Streptococcus agalactiae

and other

Streptococcus

spp.

Penicillin resistant and sensitive

Staphylococcus

spp,

Corynebacterium

spp.

Escherichia coli

and other susceptible Gram-negative bacteria.

Ampicillin has been included to destroy Gram-negative organisms which

might exist in the udder at the time of treatment to destroy any such

organisms

inadvertently

introduced

during

treatment,

reduce

substantially the incidence of new infections.

Cloxacillin is active against Gram-positive organisms, it is not destroyed

by Staphylococci penicillinase and is therefore active against penicillin

resistant Staphylococci, an important cause of mastitis. The formulation is

thus broad spectrum in activity and is bactericidal at the concentrations

achieved in the udder tissues.

INDICATIONS: Ampiclox

Dry Cow Intramammary Antibiotic Infusion is

formulated for the routine treatment of cows at drying off. It eliminates the

majority of existing infections and substantially reduces the incidence of

new infections.

Ampiclox

Intramammary Antibiotic

Infusion

particularly

recommended when the cause of infection is unidentified or where the

presence of coliforms are suspected or known to be present as a problem

on the farm.

Mastitis is a herd problem which can only be controlled by disciplined

attention to complete control programmes. Such programmes are based

on good management, but depend upon other factors including teat

dipping and routine Dry Cow therapy. Dry Cow therapy is aimed at the

elimination of the residue of infection likely to be present in cows at the

end of lactation. It will also reduce substantially the incidence of new

infections. Dry Cow formulations must be able to control these infections

and have activity against the important causitive organisms. However,

such products should avoid providing prolonged low levels of antibiotics,

which could provoke problems of resistance and give rise to antibiotic

residues in milk if calving is earlier than expected.

Ampiclox

Intramammary

Antibiotic

Infusion

been

developed

meet

these

specifications.

persistence

been

controlled to give the essential concentrations of the antibiotic over the

critical period.

Ampiclox

Dry Cow Intramammary Antibiotic Infusion is not intended for

the treatment or prevention of coliform (Gram-negative) infection at or

around

calving.

Such

Gram-negative

infections

normally

environmental origin and require specific treatment at the time with an

appropriate

lactating

product.

Ampiclox

Lactating

Intramammary Antibiotic Infusion is recommended for this purpose.

DIRECTIONS FOR USE

RESTRAINTS: DO NOT USE in lactating cows or within 30 days of

calving

PRECAUTIONS:

If

accidentally

administered

within

30

days

of

calving

or

to

a

lactating

animal,

contact

your

prescribing

veterinarian for advice.

This product should not be used in cows exhibiting sensitivity to

penicillin.

DOSE: One Syringe per quarter immediately after the final milking of a

lactation.

ADMINISTRATION:

At the final milking of a lactation, milk the cow

normally. Clean and disinfect the teat ends using rubbing alcohol or

iodophors or other suitable cleanser. Infuse the contents of one syringe

into each quarter and leave without further milking. Wear clean rubber

gloves when applying. Dip all teats after infusion, in an approved teat

disinfectant.

Any variation by the prescribing veterinarian to the approved dose,

frequency, duration, route, disease or target species may require

extending the approved withholding period.

WITHHOLDING PERIODS

MILK: DO NOT USE in lactating cows or within 30 days of calving.

After calving, milk from treated dry

cows MUST NOT BE USED for

human consumption or supplied for processing for 96 hours (8

milkings). If premature or unscheduled calving occurs, consult the

prescribing

veterinarian

for

advice

on

handling

milk

for

bobby

calves.

MEAT: DO NOT USE less than 30 days before slaughter for human

consumption.

TRADE ADVICE

EXPORT SLAUGHTER INTERVAL (ESI): This product does not have

an ESI established. For advice on the ESI contact Jurox Pty Ltd on

1800 023 312 before using this product.

FIRST AID: If poisoning occurs, contact a doctor or Poisons Information

Centre, phone 13 11 26.

DISPOSAL:

Dispose of empty container by wrapping with paper and

putting in the garbage.

STORAGE: Store below 25

C (Air Conditioning)

PRESENTATION: Ampiclox

Dry Cow Intramammary Antibiotic Infusion is

supplied in cartons of 20 syringes, or pails containing 200 syringes.

Made in Australia by:

Jurox Pty Limited

85 Gardiner Rd, Rutherford NSW 2320

Infoline 1800 023 312

APVMA Approval No. 35842/1208

405527

19-10-2018

Working Cow Homemade, Inc. Expands Recall of Ice Cream Products Because of Possible Health Risk

Working Cow Homemade, Inc. Expands Recall of Ice Cream Products Because of Possible Health Risk

Working Cow Homemade, Inc. of St. Petersburg, FL is expanding its voluntary recall to include all ice cream manufactured from August 29, 2017 – October 11, 2018, because it has the potential to be contaminated with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nause...

FDA - U.S. Food and Drug Administration

5-10-2018

Working Cow Homemade, Inc. Recalls Product Because of Possible Health Risk

Working Cow Homemade, Inc. Recalls Product Because of Possible Health Risk

Working Cow Homemade Ice Cream, Inc. of St. Petersburg, FL is conducting a voluntary recall of No Sugar Added Vanilla and No Sugar Added Chocolate ice cream manufactured in three-gallon tubs during the month of May 2018. The recall is being conducted due to a potential contamination with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only...

FDA - U.S. Food and Drug Administration

20-7-2016

Marketing authorisation for medicine for cows suspended in the EU/EEA

Marketing authorisation for medicine for cows suspended in the EU/EEA

On 14 July 2016, the Committee for Medicinal Products for Veterinary Use (CVMP) recommended that the marketing authorisation for the centrally authorised medicinal product Velactis (cabergoline) be suspended temporarily. Velactis is used to reduce milk production in dairy cows at the time of drying off. The recommendation follows reports of serious adverse events after treatment with Velactis.

Danish Medicines Agency

21-6-2016

Use of medicine for cows suspended

Use of medicine for cows suspended

Today, the Danish Medicines Agency has decided to suspend the use of the veterinary medicine Velactis, which is used to reduce milk production (drying-off) in dairy cows.

Danish Medicines Agency

There are no news related to this product.